The company is preparing a Phase 3 trial of enobosarm with a novel formulation that could extend its patent life.

"This is a situation where, had Novo Nordisk done the appropriate work upfront ... obtain statistical significance without a very large sample size. Engel is represented by Motley Rice, a firm ...

Eptinezumab use improves quality-of-life measures but does not significantly reduce the number of episodic cluster headache ...

The Obesity Drugs Market is experiencing unprecedented growth, driven by increasing global obesity rates, sedentary ...

Let's consider two corporations that could help you do better than average in the next decade: Eli Lilly (NYSE: LLY) and ...

The global drug device combination products market, valued at US$224.70 billion in 2024, stood at US$243.02 billion in 2025 ...

In the wake of early evidence supporting the long-term health benefits of GLP-1 based medications to potentially reduce the ...

Internationally, the scale is far smaller. There is not a single public company outside the US currently worth $1 trillion.

At CTO West Coast an expert from Genentech outlined the company’s net zero goals, efforts, challenges and initiatives ...

Amir Ata Saei, assistant professor at the Department of Microbiology, Tumor and Cell Biology has been awarded the Novo Nordisk Foundation Excellence ... tissue that drive these changes. By analyzing ...

Whichever way the tariff winds blow (and I've no special knowledge of that), Novo Nordisk stock remains arguably the cheapest ...

Ozempic helped Novo Nordisk gain an early lead in the weight loss industry, but competition is nipping at the company's heels ...